• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    9/17/25 4:35:59 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    false 0001737927 Canopy Growth Corp 00-0000000 0001737927 2025-09-17 2025-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): September 17, 2025

     

     

     

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Canada   001-38496   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1 Hershey Drive
    Smiths Falls, Ontario
    K7A 0A8
    (Address of principal executive offices) (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading
    Symbol(s)
    Name of each exchange
    on which registered
    Common Shares, no par value CGC The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Appointment of Permanent Chief Financial Officer

     

    On September 17, 2025, the board of directors (the “Board”) of Canopy Growth Corporation (the “Company”) appointed Thomas Stewart, who had been serving as the Company’s Chief Financial Officer on an interim basis since July 9, 2025, as the Company’s permanent Chief Financial Officer and Chief Accounting Officer (the “Appointment”).

     

    Thomas Stewart, age 43, has served as the Company’s interim Chief Financial Officer since July 2025, where he has, among other things, been responsible for overseeing all financial related matters pertaining to the Company. In addition, Mr. Stewart served as the Company’s Vice President, Finance from August 2023 until July 2025, where he was responsible for a wide range of the Company’s finance functions, including external reporting, financial close technical accounting, financial close processes, transactional services, tax, FP&A, commercial finance, and operations finance. Prior to that role, Mr. Stewart served as the Company’s Chief Accounting Officer from April 2019 until August 2023. Prior to joining the Company in April 2019, Mr. Stewart spent over 10 years at Constellation Brands, Inc., where he held a variety of roles within the finance organization, most recently serving as Senior Director, Global Accounting from June 2018 to April 2019. Mr. Stewart started his career at PricewaterhouseCoopers in Rochester, NY and obtained his Bachelor of Science in Accounting from the State University of New York at Geneseo. Mr. Stewart is a Certified Public Accountant in the state of New York and brings a wealth of U.S. GAAP experience to the Company.

     

    There are no arrangements or understandings between Mr. Stewart and any other person pursuant to which he was selected as Chief Financial Officer. Mr. Stewart does not have any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Mr. Stewart and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

     

    Employment Agreement with Thomas Stewart

     

    In connection with the Appointment as Chief Financial Officer of the Company, on September 17, 2025, Mr. Stewart entered into an employment agreement with Canopy Growth USA, LLC, a wholly-owned subsidiary of the Company (the “Employment Agreement”). Pursuant to the Employment Agreement, as Chief Financial Officer of the Company, Mr. Stewart reports to the Chief Executive Officer of the Company and is entitled to a base salary of US$375,000 per year.

     

    Mr. Stewart is also eligible for a short-term annual incentive performance bonus of 75% of his base salary (the “Target Amount”), with a payout range of up to two times the Target Amount based upon the achievement of certain mutually developed financial, operational, strategic and individual performance objectives approved by the Board.

     

    Mr. Stewart is also entitled to participate in the Company’s Amended and Restated Omnibus Equity Incentive Plan (the “Incentive Plan”). Pursuant to the Employment Agreement, Mr. Stewart is eligible to receive, at least once every fiscal year, a long-term award grant equal to 200% of his base salary (using the fair market value of the Company’s common shares on the date of grant), which may be comprised of stock options (“Options”), restricted stock units (“RSUs”), performance share units and/or any other form of equity authorized by the Incentive Plan. The Board, in its sole discretion, may determine the ratio of the various forms of equity that Mr. Stewart is entitled to receive pursuant to the Incentive Plan.

     

    In connection with the Appointment and pursuant to the Employment Agreement, on September 17, 2025, Mr. Stewart will receive a one-time equity award grant consisting of (i) such number of RSUs as is equal to $250,000 divided by Fair Market Value (as such term is defined in the Incentive Plan) of the Company’s common shares (the “Common Shares”) and (ii) a number of Options equal to $250,000 divided by the Fair Market Value of the Common Shares with an exercise price equal to the Fair Market Value of the Common Shares (the “Equity Award”). The Equity Award will vest in three equal installments on the first, second and third anniversaries of the grant date, and the Options have a six-year term.

     

     

    Pursuant to the Employment Agreement, Mr. Stewart’s employment with the Company will be “at will.” If the Company terminates Mr. Stewart’s employment without cause, then, provided that Mr. Stewart signs and returns to the Company a full and final employment separation, release and waiver of liability, the Company will provide (a) a payment or payments equal to 18 months’ base salary by way of lump sum or on salary continuance at the discretion of the Company, provided if the Company elects to pay by lump sum, payment will be payable no later than two and a half months following the end of the calendar year in which the termination occurs; (b) a lump sum payment equal to 150% of the average actual annual amounts paid as a short-term annual incentive performance bonus during the prior two years, which will be payable no later than two and a half months following the end of the calendar year in which the termination occurs; (c) any outstanding performance share units will vest at actual performance levels for all years already certified by the Board or any responsible committee thereof; and (d) if Mr. Stewart were to elect continuation coverage under the Company’s medical plan pursuant to COBRA, a reimbursement to Mr. Stewart for a portion of COBRA premium payments as further described in the Employment Agreement. The Company may also terminate Mr. Stewart’s employment with cause, without further liability to Mr. Stewart.

     

    The Employment Agreement contains certain non-competition and non-solicitation provisions in favor of the Company for a period of 18 months following the termination of the Employment Agreement.

     

    The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Report”).

     

    Item 7.01Regulation FD Disclosure.

     

    On September 17, 2025, the Company issued a press release titled “Canopy Growth Appoints Tom Stewart as Chief Financial Officer,” a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein solely for purposes of this Item 7.01 disclosure.

     

    The information set forth and incorporated by reference in Item 7.01 of this Report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information set forth and incorporated by reference in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Employment Agreement, effective as of September 17, 2025, between Canopy Growth USA, LLC and Thomas Stewart.
    99.1   Press Release, dated September 17, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CANOPY GROWTH CORPORATION
         
      By: /s/ Christelle Gedeon
        Christelle Gedeon
        Chief Legal Officer

     

    Date: September 17, 2025

     

     

    Get the next $CGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Corporation Announces Adjournment of Annual General and Special Meeting of Shareholders Due to Lack of Quorum

    Annual General and Special Meeting of Shareholders of Canopy Growth to be reconvened on October 10 at 1:00 PM ET Canopy Growth shareholders now have until 1:00 PM ET on October 8 to vote Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ: CGC) today announced that, due to the requisite quorum not being present, the annual general and special meeting of shareholders (the "Meeting") scheduled for September 26, 2025 at 1:00 p.m. Eastern Time via live webcast was convened and then adjourned

    9/26/25 2:00:00 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General and Special Meeting

    Shareholders now have until September 26, 2025 at 9:00 AM ET to submit votes to help ensure a quorum is achieved Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today that it has extended the deadline for the submission of proxies related to its upcoming annual general and special meeting of shareholders (the "Meeting") to September 26, 2025 at 9:00 AM ET. The Meeting will be held later the same day, at 1:00 PM ET via live audio webcast at www.virtualshareholdermeeting.c

    9/24/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Urges Shareholders to Cast their Vote for the Upcoming Annual General and Special Meeting Today

    Shareholders are encouraged to vote well in advance of the proxy deadline on September 24, 2025 at 1:00 PM ET The Board of Directors of Canopy Growth recommends shareholders vote FOR each proposal Your vote is important! If you need assistance with voting your shares, please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) today urges its shareholders to vote ahead of the upcoming annual general and special meeting of shareholders (the "Meeting") on September 26, 2025 at 1:00 PM ET. Canopy Needs Your Vote – Vote Today and Help Us Reach Quorum Canopy

    9/19/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    9/26/25 2:49:17 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    9/24/25 4:15:25 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    9/19/25 4:15:17 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Canopy Growth with a new price target

    Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

    11/2/22 6:11:10 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Canopy Growth from Sell to Hold

    10/26/22 7:36:52 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Stewart Thomas Carlton was granted 178,462 shares, increasing direct ownership by 262% to 246,665 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/19/25 4:15:18 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Stewart Thomas Carlton sold $10,036 worth of shares (5,768 units at $1.74), decreasing direct ownership by 8% to 68,203 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    8/26/25 4:15:57 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year

     Canada adult-use cannabis Q1 FY2026 net revenue increased 43% year-over-year, benefiting from increased distribution and strong consumer demand for new products, including Claybourne infused pre-roll joints Company has achieved $17MM of planned $20MM annualized savings target since March 1, 2025; SG&A expenses down 21% year-over-year in Q1 FY2026 compared to Q1 FY2025 Supply chain improvements in international markets expected to increase cannabis supply and consistency in margin accretive European markets in the second half of FY2026 Company expects to launch a new Storz & Bickel vaporizer during the second half of the calendar year Canopy Growth Corporation ("Canopy Growth" or th

    8/8/25 7:00:00 AM ET
    $CGC
    $DRI
    Medicinal Chemicals and Botanical Products
    Health Care
    Restaurants
    Consumer Discretionary

    Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2026 ended June 30, 2025 before financial markets open on August 8, 2025. Following the release of its first quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, Interim CFO on August 8, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=8135284A-F8CD-45B7-A384-634DE6714986 Replay Information A replay will be accessible by webcast until 11:59 PM ET on November 6, 2025 at:

    7/25/25 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a

    5/30/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Appoints Tom Stewart as Chief Financial Officer

    Appointment finalizes CFO transition and reinforces Canopy Growth's focus on operational discipline, financial stability, and long-term value creation Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately. Mr. Stewart's appointment supports the continued execution of Canopy Growth's fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progres

    9/17/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy USA Welcomes Cannabis Veteran Eric Ruhle as New Vice President of Brand Sales

    BOULDER, Colo., Aug. 27, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the U.S. cannabis market, today announced the appointment of Eric Ruhle as Vice President of Brand Sales, overseeing sales strategy across the full Canopy USA portfolio. With more than 11 years of experience in the regulated cannabis industry, Ruhle brings deep expertise in building and leading high-performing sales organizations. Most recently, he served as Senior Regional Sales Manager at Kiva Sales & Services, where he navigated the highl

    8/27/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market

    New leaders will be responsible for driving portfolio growth, operational improvements, and market expansion BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. cannabis market, today announced the appointment of a new executive team responsible for driving the Company's next phase of expansion. Drawing on extensive industry experience, these leaders will steer Canopy USA forward through a shared vision to elevate the compa

    8/18/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care